BioXcel Therapeutics (BTAI) Change in Receivables (2023 - 2026)
BioXcel Therapeutics (BTAI) posted Change in Receivables of -$134000.0 for Q2 2026, down 688.24% on a QoQ basis from -$17000.0 in Q1 2026, and down 888.24% year-over-year from $17000.0 in Q2 2025.
Powered by 
Analysis
BioXcel Therapeutics (BTAI) Change in Receivables (2023 - 2026) Analysis & Trends
BioXcel Therapeutics has reported Change in Receivables for 4 years, with the latest figure at -$134000.0 in Q2 2026.
- On a quarterly basis, Change in Receivables fell 888.24% year-over-year to -$134000.0 in Q2 2026; TTM through Jun 2026 was $65000.0, a 108.18% increase from a year earlier, with the FY2025 full-year figure at $102000.0, up 70.0% from the prior year.
- Change in Receivables was -$134000.0 for Q2 2026 at BioXcel Therapeutics, down from -$17000.0 in the prior quarter.
- The five-year high for Change in Receivables was $434000.0 in Q2 2024, with the low at -$809000.0 in Q3 2024.
- Average Change in Receivables over 4 years is -$11857.1, with a median of $26000.0 recorded in 2023.
- The sharpest annual moves came in 2024 and 2026: Change in Receivables surged 777.14% in 2024, then tumbled 888.24% in 2026.
- Over 4 years, Change in Receivables stood at -$664000.0 in 2023, then soared by 119.28% to $128000.0 in 2024, then soared by 82.03% to $233000.0 in 2025, then plunged by 157.51% to -$134000.0 in 2026.
- The last three Change in Receivables figures came in at -$134000.0 (Q2 2026), -$17000.0 (Q1 2026), and $233000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | 1.09 Bn |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | 333.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | 140.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | 838.50 Mn |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | -53.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | 269.40 Mn |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | - |
| 10 | BioXcel Therapeutics | 2.19 Mn | 2.19 Mn | 160,000.00 | -134,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -134,000.00 |
| Mar 31, 2026 | -17,000.00 |
| Dec 31, 2025 | 233,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Mar 31, 2025 | -131,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Sep 30, 2024 | -809,000.00 |
| Jun 30, 2024 | 434,000.00 |
| Mar 31, 2024 | 307,000.00 |
| Dec 31, 2023 | -664,000.00 |
| Sep 30, 2023 | 304,000.00 |
| Jun 30, 2023 | 148,000.00 |
| Mar 31, 2023 | 35,000.00 |